Effect of pyridoxine supplementation on recurrent stone formers.
Twelve recurrent stone formers with hyperoxaluria were administered pyridoxine-HCl (10 mg/day) daily for a period of 180 days. The pyridoxine status of the patients, as assessed by their erythrocyte transaminase activation indexes, improved significantly (p less than 0.001) after 180 days of supplementation as compared with the basal levels. Although urinary oxalate decreased significantly (p less than 0.05) by the 90th day of pyridoxine therapy, other parameters, e.g., urinary calcium, phosphorus, and creatinine, remained unaltered. Significant correlation was observed between erythrocyte glutamate pyruvate transaminase (EGPT) or erythrocyte glutamate oxaloacetate transaminase (EGOT) activation index and urinary oxalate excretion (p less than 0.01). Pyridoxine in low doses (10 mg/day) is of therapeutic value for hyperoxaluric stone formers.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002118:Calcium / Q000652:urine; D006801:Humans; D010070:Oxalates / Q000652:urine; D010758:Phosphorus / Q000652:urine; D011736:Pyridoxine / Q000627:therapeutic use*; D012008:Recurrence; D013997:Time Factors; D014545:Urinary Calculi / Q000517:prevention & control*
D010070:Oxalates; D010758:Phosphorus; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D011736:Pyridoxine; D002118:Calcium